On the will to ignorance in bureaucracy

Economy and Society

Volumn 36, Issue 2, 2007, Pages 212-235

  McGoey, Linsey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUREAUCRACY; RISK; THEORETICAL STUDY;

EID: 34047179018     PISSN: 03085147     EISSN: 14695766     Source Type: Journal    
DOI: 10.1080/03085140701254282     Document Type: Article

References (61)

1. Abraham, J. (2001) A licence to print money?. Healthmatters
2. Abraham, J. (2002) Transnational industrial power, the medical profession and the regulatory state: Adverse drug reactions and the crisis over the safety of Halcion in the Netherlands and the UK. Social Science & Medicine, 55, pp. 1671-1690.
3. Abraham, J. and Sheppard, J. (1999) Complacent and conflicting scientific expertise in British and American drug regulation: Clinical risk assessment of Triazolam. Social Studies of Science, 29, pp. 803-843.
4. (2003) Regulation of the Pharmaceutical Industry, Palgrave Macmillan
5. (2006) Did regulators fail over SSRIs?.
6. Arendt, H. (1969) On Violence, Harcourt Brace, New York
7. Beasley, C., Dornseif, B., Bosomworth, J., Sayler, M., Rampey, A. and Heiligenstein, J. (1991) Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression. British Medical Journal, 303, pp. 685-692.
8. Blau, P. (1956) Bureaucracy in Modern Society, Random House, New York
9. Boseley, S. (2004) Drug safety agency accused of cover-up. Guardian
10. Bourdieu, P. (1990) Other Words: Essays towards a Reflexive Sociology, Polity Press
11. Breggin, P. (2003) Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis. International Journal of Risk & Safety in Medicine, 16, pp. 31-49.
12. Crozier, M. (1964) The Bureaucratic Phenomenon, Tavistock, London
13. Deleuze, G. (2006) Foucault, Continuum, London and New York
14. DiMaggio, P. and Powell, W. (1983) The iron cage revisited: institutional isomorphism and collective rationality in organizations. American Sociological Review, 48, pp. 147-160.
15. Donovan, S., Kelleher, M. J., Lambourn, J. and Foster, T. (1999) The occurrence of suicide following the prescription of antidepressant drugs. Archives of Suicide Research, 5, pp. 181-192.
16. Donovan, S., Clayton, A., Beeharry, M., Jones, S., Kirk, C., Waters, K., Gardner, D., Faulding, J. and Madely, R. (2000) Deliberate self-harm and antidepressant drugs: Investigation of a possible link. British Journal of Psychiatry, 177, pp. 551-556.
17. Gay, P. du (2005) The Values of Bureaucracy, Oxford University Press, Oxford
18. (1991)
19. Ferguson, J. (1990) The Anti-Politics Machine: 'Development', Depoliticization and Bureaucratic Power in Lesotho, University of Minnesota Press
20. Fergusson, D., Doucette, S., Glass, K. Cranley, Shapiro, S., Healy, D., Herbert, P. and Hutton, B. (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomised controlled trials. British Medical Journal, 330, p. 396.
21. Foucault, M. (1980) Power/Knowledge: Selected Interviews and Other Writings (1972-1977), Random House, New York
22. Foucault, M. (1984) Nietzsche, genealogy, history. The Foucault Reader, pp. 76-100. Penguin, London
23. Foucault, M. (2003) Society Must be Defended, Penguin, London
24. Fraser, M. (2006) Moral measures: Ethics, method and Prozac.
25. Gibbons, R. D., Hur, K., Bhaumik, D. K. and Mann, J. J. (2005) The relationship between antidepressant medication use and rate of suicide. Archives of General Psychiatry, 62, p. 165.
26. Graeber, D. (2006) Beyond power/knowledge: An exploration of the relationship of power, ignorance and stupidity.
27. Healy, D. (1994) The fluoxetine and suicide controversy: A review of the evidence. CNS Drugs, 1, pp. 223-231.
28. Healy, D. (2000) Emergence of antidepressant induced suicidality. Primary Care Psychiatry, 6, pp. 23-18.
29. Healy, D. (2004) Let Them Eat Prozac: The Unhealthy Relationship between the Pharmaceutical Industry and Depression, New York University Press, New York and London
30. (2005) House of Commons, UK Parliament: The Influence of the Pharmaceutical Industry: Fourth Report of the Session 2004-05, 1, The Stationery Office
31. (2005) House of Commons, UK Parliament: The Influence of the Pharmaceutical Industry: Fourth Report of the Session 2004-05, 2, The Stationery Office
32. Hurcombe, L. (2004) Losing a Child: Explorations in Grief, Sheldon Press, London
33. Jick, S. S., Dean, A. D. and Jick, H. (1995) Antidepressants and suicide. British Medical Journal, 310, pp. 215-218.
34. Kahn, A., Warner, H. and Brown, W. (2000) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration database. Archives of General Psychiatry, 47, pp. 311-317.
35. Kendall, T., Pilling, S. and Whittington, C. (2005) Are the SSRIs and atypical antidepressants safe and effective for children and adolescents?. Current Opinions in Psychiatry, 18, pp. 21-25.
36. Kondro, W. (2004) Drug company experts advised staff to withhold data about SSRI use in children. Canadian Medical Association Journal, 170, p. 783.
37. Landy, J. (2002) Nietzsche, Proust, and will-to-ignorance. Philosophy and Literature, 26, pp. 1-13.
38. Lenzer, J. (2006) Manufacturer admits increase in suicidal behaviour in patients taking paroxetine. BMJ, p. 332.
39. Licinio, J. and Wong, M. -L. (2005) Depression, antidepressants and suicidality: A critical appraisal. Nature, p. 4.
40. Luhmann, N. (1998) Ecology of ignorance. Observations on Modernity, Stanford University Press, Stanford, CA
41. Majone, G. (2002) What price safety? The precautionary principle and its policy implications. Journal of Common Market Studies, 40, pp. 89-109.
42. Markowitz, J. C. (2001) Antidepressants and suicide. The British Journal of Psychiatry, p. 178.
43. Medawar, C. and Hardon, A. (2004) Medicines out of Control? Antidepressants and the Conspiracy of Goodwill, Aksant Academic, Amsterdam
44. (2004)
45. (2006) Personal email correspondence from Anne Thyer, Policy Division regarding Section 118.
46. Morgan, O., Griffiths, C. and Baker, A. (2005) Geographical variations in fatal poisoning due to antidepressant drugs in England and Wales, 1993-2003. Health Statistics Quarterly, 27, pp. 2-12.
47. Mossialos, E., Mrazek, M. F. and Walley, T. (2004) Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality, Open University Press, Milton Keynes
48. Nehamas, A. (1985) Nietzsche: Life as Literature, Harvard University Press, Cambridge, MA, and London
49. Nietzsche, F. (1990) Beyond Good and Evil, Penguin Classics, London
50. Nutt, D. (2003) Death and dependence: Current controversies over the selective serontonin reuptake inhibitors. Journal of Psychopharmacology, 14, pp. 355-364.
51. Power, M. (1994) The Audit Explosion, White Dove Press, London
52. Power, M. (2003) Auditing and the production of legitimacy. Accounting, Organizations and Society, 28, pp. 379-394.
53. Proctor, R. (1996) Cancer Wars: How Politics Shapes What We Know and Don't Know about Cancer, HarperCollins, New York
54. Rabinow, P. (2004) Assembling ethics in an ecology of ignorance.
55. Reed, M. (2005) Beyond the iron cage. The Values of Bureaucracy, Oxford University Press, Oxford
56. Rose, N. (1999) Powers of Freedom: Reframing Political Thought, Cambridge University Press, Cambridge
57. Stipp, D. (2005) Prozac Backlash: Trouble in Prozac. Fortune Magazine
58. Taussig, M. (1999) Defacement: Public Secrecy and the Labor of the Negative, Stanford University Press, Stanford, CA
59. Teicher, M., Glod, C. and Cole, J. (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry, 147, pp. 207-210.
60. Weber, M. (1922) The development of bureaucracy and its relation to law. Weber: Selections in Translation, Cambridge University Press, Cambridge
61. Weber, M. (1978) Economy and Society, 2, University of California Press